Literature DB >> 28698755

Primary Fallopian Tube Carcinoma: A Case Report and Literature Review.

Meral Rexhepi1, Elizabeta Trajkovska2, Hysni Ismaili3, Florin Besimi1, Nagip Rufati1.   

Abstract

BACKGROUND: Primary fallopian tube carcinoma (PFTC) is a rare tumour of the female genital tract with an incidence of 0.1-1.8% of all genital malignancies, and it is very difficult to diagnose preoperatively, because of its non-specific symptomatology. In most cases, it is an intraoperative finding or a histopathological diagnosis. It is a tumour that histologically and clinically resembles epithelial ovarian cancer. CASE
PRESENTATION: We are reporting a case of a 62-year-old, postmenopausal women with primary fallopian tube carcinoma of the right fallopian tube in stage IA. The patient has lower abdominal pain, watery vaginal discharge and repeated episodes of bleeding from the vagina. The clinical and radiological findings suggested a right adnexal tumour with elevated CA-125 levels. Total abdominal hysterectomy, bilateral salpingo-oophorectomy, omentectomy and peritoneal washing were performed. Pathologic confirmation of primary serous cystadenocarcinoma of the right fallopian tube was made. Peritoneal washings were negative for malignancy. FIGO stage was considered as IA, and the patient received no courses of chemotherapy and postoperative radiation because she refused it. Ten months after initial surgery, the patient is alive and in good condition.
CONCLUSION: Cytoreduction surgery followed by adequate cycles of chemotherapy is an important strategy to improve patients' prognosis.

Entities:  

Keywords:  fallopian tube; histopathological diagnosis; intraoperative assessment; post-menopausal female; serous cystadenocarcinoma

Year:  2017        PMID: 28698755      PMCID: PMC5503735          DOI: 10.3889/oamjms.2017.044

Source DB:  PubMed          Journal:  Open Access Maced J Med Sci        ISSN: 1857-9655


Introduction

Primary fallopian tube carcinoma (PFTC) is a very rare gynecologic malignant tumor and accounts for approximately 0.14-1.8% of female genital malignancies [1-7]. In 1847, Renaud first described fallopian tube malignancy. In 1888, Orthmann presented the first genuine case report [7]. Since then over 2000 case have been reported in literature. Its incidence has been rising during the last decades and varied between 2.9/1,000,000 and 5.7/1,000,000 [8]. Histologic, molecular and genetic evidence shows that from 40-60% of tumours that were classified as high-grade serous carcinomas of the ovary or peritoneum may have originated in the fimbrial and of the fallopian tube. Therefore the incidence of fallopian tube cancers may have been underestimated [9]. The aetiology of this tumour is unknown enough; it is suggested to be associated with chronic tubal inflammation, infertility, tuberculous salpingitis and tubal endometriosis [10]. Similar to ovarian malignancy, a BRCA germline mutation and TP53 mutation are associated with fallopian tube malignancy [11, 12]. Clinical symptoms and sings are non-specific and include lower abdominal, pelvic pain, serosanguinous vaginal discharge and pelvic mass [13, 14]. The rate of preoperative diagnosis was in the range of 0%-10% [15] and most cases it is an intraoperative finding or a histopathological diagnosis [16]. We are reporting a rare case of fallopian tube carcinoma in a 62-year-old female, with a review of the literature.

Case Report

We present a 62-year-old, post menopausal women who was gravid 4, para 2, living child 2 (Parity Index –G4P2L2), married, with no significant personal or family history. Her two deliveries were spontaneous vaginal deliveries, and she had been post-menopausal since past 16 years. She presented with the complaints of severe lower abdominal pain and intermittent vaginal bleeding and discharge that had occurred for the previous six months. The abdominal pain was a dull ache in the right lower abdomen which propagated to the back. The vaginal discharge was watery in consistency. For her medical history, she had taken antihypertension medication for the past eight years. On the admission day, her blood pressure was 140/90 mmHg, the puls rate was 80 beats per minute, and her temperature was 37.5°C. She had already tried conservative treatment, which had not improved her symptoms. Her hemogram, hepatic and renal functions were normal. Blood sugar and urine examination were normal. On the physical examination was noticed left lateral lower quadrant tenderness. The pelvic examination revealed a normal sized anteverted uterus with cervical motion and adnexal tenderness. Speculum examination showed minimal bleeding with a healthy cervix and vagina. Transabdominal sonography showed uterus with normal echostructure, measuring 64x52x38 mm. Endometrial thickness was 5 mm. Left ovary measured 20 x 15 x 10 mm and had normal echostructure. Unilateral heterogenous longitudinal mass, multilocular cyst with incomplete septation showed in the right adnexa, and the mass measured 7.2 x 4.6, which suggested right tube-ovarian abscess. Transabdominal ultrasonography showing a multilocular cyst with incomplete septation Free fluid was not seen in the abdomen. Computerised tomography (CT) was not done. The white cell count on admission was 18.4 x 109/L, and the C-reactive protein level was 14.26 mg/dl. The Ca 125 antigen level was 162.20 U/ml (normal up to 35 U/ml), the Ca 19-9 and CEA levels was normal. Based on the clinical pictures and laboratory results a right tube-ovarian abscess was suspected, and broad spectrum parenteral antibiotics were established. The Pap smear was within normal limits. A diagnostic curettage was performed which showed atrophic endometrium. In exploratory laparotomy was found hydrosalpinx on the right side with severe adhesions between the right adnexa, intestine and uterus. The patient underwent total abdominal hysterectomy, bilateral salpingo-oophorectomy, partial omentectomy with adhesiolysis and peritoneal washing was performed. The bilateral ovarian masses, fallopian tubes, uterus, omentum and sample of peritoneal washing were sent for histopathological analysis. The histopathologic examination showed primary serous cyst adenocarcinoma of the right fallopian tube with no serosa invasion. The tuba was tortuous, 17 cm in length with 5 cm long dilatation in the proximal third. In the dilated part, few exophytic, neoplastic, white-grayish soft lesions were found. Tortuous fallopian tube (up), exophytic, neoplastic white grayish soft lesions (down) The histopathologic examination revealed areas of in situ as well as high-grade primary serous adenocarcinoma of the fallopian tube with lamina propria involvement. a) HE x 4 Adenocarcinoma tube; b) HE x 10 intact musculature; c) HE x 40 malignant epithelium The malignant cells were positive for CK7, WT1 and P53, the tumour did not infiltrate the muscle layer, so it was defined as FIGO stage IA (pTNM = pT1A pNx pMx stage IA). The uterus, ovaries, left the fallopian tube and the peritoneal washing fluid was free of tumour. In our case the pre-operative diagnosis was incorrect. This is the fact that Fallopian tube carcinomas are almost difficult to diagnose preoperatively due to the rarity and silent course of this neoplasm. The patient was discharged, seven days after the surgery and was referred to an oncologist for chemotherapy.

Discussion

Primary Fallopian tube carcinoma is the rarest malignancy of the female genital tract and was first described by Renand in 1897 [17]. Rokitansky recorded the first microscopic description in 1861 and Orthman presented a first case report in 1888 [18]. Clinically and histologically (PFTC) resemble epithelial ovarian cancer (EOC), and it is difficult to distinguish from serious epithelial ovarian cancer or primary peritoneal serous carcinoma during or after operation [19]. a) CK7 x 10 immunostaining positive with CK7 antibody; b) WT1 x 20 immunostaining positive with WT1 antibody; c) P53 x 20 immunostaining positive with P53 antibody EOC is often diagnosed at an advanced stage, but PFTC is found more in an early stage, because of abdominal pain from tubal distension and a shorter history of symptoms in PFTC than in EOC [20]. The aetiology of this cancer is unknown. High parity has been reported to be protective, and use of oral contraceptives and pregnancy decreases the risk of PFTC [8]. Most patients with PFTC are postmenopausal. The peak incidence is between the ages 60 and 64 years, with the mean age of incidence being 55 years (age range 17-88 years) [21]. Our patient was postmenopausal. She doesn’t have a predisposing factor. Pelvic inflammatory disease, nulliparity and subfertility were not present in our case. The clinical symptoms and signs of PFTC are not specific. The most common symptoms and signs are abdominal pain, which may be colicky as a result of forced tubal peristalsis or dull as a result of tubal distension and vaginal bleeding or watery discharge [22]. The Latzko’s triad of typical symptoms consists of intermittent profuse serosanguinous vaginal bleeding, colicky pain relieved by discharge and an abdominal or pelvic mass. This triad was reported in only 15% of PFTC cases [14]. In our case, all of these symptoms were presented. In most cases, the preoperative diagnosis of PFTC is extremely rare [23]. The rate of preoperative diagnosis was in the range of 0%-10% [24], and up to 50% are missed intraoperatively [25]. PFTC should be included in the differential diagnosis and if the patient has clinical symptoms such as vaginal discharge or abnormal genital bleeding or spotting with negative diagnostic curettage. Pap smear positivity occurs in 10%-36% of cases [14, 26]. In our patient diagnostic curettage and Pap smear were negative. The CA-125 level is raised. Ca-125 is a useful tumour marker for the diagnosis, assessment of response to treatment and detection of tumour recurrence during follow-up. 80% of patients with PFTC have elevated pretreatment serum levels of CA 125 [27]. The diagnostic criteria for PFTC were first established by Hu and colleagues and later slightly modified by Sidles. Accordingly, PFTC is diagnosed if: grossly, the main tumor is in the tube and arises from the endo salpinx; the histological pattern reproduces the epithelium of tubal mucosa; transition from benign to malignant tubal epithelium should be demonstrated, and ovaries and endometrium are either normal or have a much smaller tumor volume than that of the tube [28, 29]. Approximately 90% of ovarian cancers are carcinomas (malignant epithelial tumors) and based on histopathology, immunohistochemistry and molecular genetic analyzes, at least 5 main types are currently distinguished: high-grade serous carcinoma (HGSC, 70%); endometrioid carcinoma (EC, 10%); clear-cell carcinoma (CCC, 10%); mucinous carcinoma (MC, 3%); and low-grade serous carcinoma (LGSC, <5%) [30]. Imaging for suspected gynecologic malignancies includes ultrasound, computed tomography (CT) scan and magnetic resonance imaging (MRI) of the abdomen. Transvaginal and transabdominal ultrasound is the simplest and usually initial imaging investigation. Although the ultrasound findings of tubal carcinoma are nonspecific and mimic other pelvic diseases such as an ovarian tumour or tube-ovarian abscess, several findings may provide a diagnostic clue preoperatively. The echogram may show a cystic mass with spaces and mural nodules, a sausage-shaped mass or a multilobular mass with a cog-and-wheel appearance [31, 32]. The lesion can have the appearance of a small, solid, lobulated mass on CT scan or MRI. On CT scan, a solid papillary intratubal mass allows for easy prediction of PFTC. MRI is considered a better method than CT or ultrasound for detecting tumour infiltration of extramural organs [33]. Surgery is the treatment of choice for PFTC and is similar to that for ovarian carcinoma-cytoreductive surgery with the removal of the tumour as much as possible. The procedure of choice is total abdominal hysterectomy, bilateral salpingo-oophorectomy, omentectomy, selective pelvic and para-aortic lymphadenectomy for any stage of fallopian tube carcinoma [9, 13]. Postoperative platinum- based combination adjuvant chemotherapy is the most commonly used therapy for these patients, similar to EOC patients. The role of postoperative radiotherapy is even less clear [4, 9]. The reported overall responses rates are 53-92%. The stage of disease at the time of diagnosis is the most important factor affecting the prognosis [6]. The other prognostic factors include the residual volume of the tumour after cytoreduction, the presence of ascites and the histologic grade of the tumour [6, 9]. In conclusion, primary fallopian tube carcinoma is a rare gynecologic malignancy that accounts for less than 1% of all malignancies of the female genitalia. Preoperative diagnosis of fallopian tube carcinoma is difficult due to the silent course of this neoplasm and is usually first appreciated at the time of operation or by a pathologist. PFTC histologically and clinically resembles epithelial ovarian carcinoma. The symptom complex of “hydrops tube pro fluence” said to be pathognomonic for this tumour, is rarely encountered. It should be considered in differential diagnosis of peri and postmenopausal women who present with unexplained uterine bleeding, pelvic pain, adnexal mass, abnormal cervical smear and complicated pelvic inflammatory disease. The treatment approach is similar to that of ovarian carcinoma, and it should consist of a total abdominal hysterectomy with bilateral salpingo-ovariectomy, omentectomy and lymph node dissection from the pelvic and the para-aortic regions.
  26 in total

1.  Primary adenocarcinoma of fallopian tube--a case report.

Authors:  R Kalyani; M L Harendra Kumar; S H Srikantia
Journal:  Indian J Pathol Microbiol       Date:  2005-04       Impact factor: 0.740

2.  Carcinoma of the fallopian tube.

Authors:  A Sedlis
Journal:  Surg Clin North Am       Date:  1978-02       Impact factor: 2.741

Review 3.  Revised FIGO staging system for cancer of the ovary, fallopian tube, and peritoneum: important implications for radiologists.

Authors:  Tsukasa Saida; Yumiko Oishi Tanaka; Koji Matsumoto; Toyomi Satoh; Hiroyuki Yoshikawa; Manabu Minami
Journal:  Jpn J Radiol       Date:  2015-12-22       Impact factor: 2.374

Review 4.  Fallopian tube carcinoma: a review.

Authors:  Dimitrios Pectasides; Eirini Pectasides; Theofanis Economopoulos
Journal:  Oncologist       Date:  2006-09

5.  Serous fallopian tube carcinoma: a retrospective, multi-institutional case-control comparison to serous adenocarcinoma of the ovary.

Authors:  Kathleen N Moore; Katherine M Moxley; Amanda Nickles Fader; Allison E Axtell; Rodney P Rocconi; Lisa N Abaid; Ilana A Cass; Peter G Rose; Charles A Leath; Teresa Rutledge; Derek Blankenship; Michael A Gold
Journal:  Gynecol Oncol       Date:  2007-11-07       Impact factor: 5.482

6.  Analysis of 23 cases of primary carcinoma of the fallopian tube over 50 years.

Authors:  M M Huber-Buchholz; N P Buchholz; J Staehelin
Journal:  J Obstet Gynaecol Res       Date:  1996-06       Impact factor: 1.730

Review 7.  Determinants of incidence of primary fallopian tube carcinoma (PFTC).

Authors:  Annika Riska; Arto Leminen
Journal:  Methods Mol Biol       Date:  2009

8.  Primary bilateral fallopian tube carcinoma the report of a single case with review of the literature.

Authors:  Prajna Hariprasad; Hariprasad S; Teerthanath Srinivas; Jayrama Shetty K
Journal:  J Clin Diagn Res       Date:  2013-03-07

9.  Primary carcinoma of the fallopian tube: a 20-year literature review.

Authors:  A J Nordin
Journal:  Obstet Gynecol Surv       Date:  1994-05       Impact factor: 2.347

10.  Primary fallopian tube carcinoma: review of MR imaging findings.

Authors:  Filipe Veloso Gomes; João Lopes Dias; Rita Lucas; Teresa Margarida Cunha
Journal:  Insights Imaging       Date:  2015-07-07
View more
  2 in total

1.  Fallopian Tube Tumor Mimicking Primary Gastrointestinal Malignancy.

Authors:  Anupam K Gupta; Oscar A Vazquez
Journal:  Cureus       Date:  2020-08-17

2.  Port-site metastasis as a primary complication following diagnostic laparoscopy of fallopian tube carcinoma: A case report.

Authors:  Yan Chen; Chen Ling; Ce Bian
Journal:  Medicine (Baltimore)       Date:  2018-06       Impact factor: 1.889

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.